KR100389132B1 - Mixed extracted substance having anti-oxidant activity from aralia and rubus - Google Patents

Abstract

The present invention relates to a composition that has a powerful antioxidant activity as an extract of aralia and raspberries, which has the effect of preventing, delaying, and treating diseases such as cataracts due to aging, and extracting rasp and raspberries with water or alcohol. This extract can be used in admixture with other known antioxidants, including myo-inositol or taurine to achieve synergistic effects in cataract treatment. In addition, it is possible to obtain a drink by the drink containing the extract of arsame and raspberry as an active ingredient, it is possible to obtain the effects of prevention, delay and treatment for various diseases caused by aging.

Description

MIXED EXTRACTED SUBSTANCE HAVING ANTI-OXIDANT ACTIVITY FROM ARALIA AND RUBUS}

The present invention relates to an antioxidant composition in which arbor and raspberries are extracted with a solvent, and more particularly, by extracting arbor and raspberries with water or alcohol, the extract is administered to an animal to prevent oxidation of cell membranes or various oxidations occurring in vivo. It participates in the reaction and helps to maintain the health by suppressing excessive oxidation. For example, by effectively removing the excess peroxide produced in the living body to prevent or treat diseases such as cataracts.

The living body contains a large amount of unsaturated fatty acids, which form the essential structure of the cell membrane and give the organisms the flexibility to adapt to the environment. Unsaturated fatty acids, however, are known to be easily damaged by free radicals and peroxide chemical reactions in the process of oxygen metabolism, which promotes aging and eventually death. In general, 40-50% of the cell membrane of the living body is composed of lipids, except for myelin neurite process is about 80% of the lipid and the inner membrane of the mitochondria is about 20% of the lipid. 50-85% of the lipids are phosphoglycerides, in which two fatty acid chains are formed by ester bonds to glycerol molecules. All biofilms consist of lipid bilayers that show hydrophobicity on the inside and hydrophilic on the outside. The lipid bilayer has a very stable structure and changes in fluidity with temperature.

The large amount of unsaturated fatty acids that make up the cell membrane is metabolized to acetyl co A (acetyl coemzyme A) by the beta oxidation during the respiratory chain in the inner membrane of the mitochondria. In this case, free radicals that are highly reactive with a large amount of peroxides of unsaturated fatty acids are generated, and the low lipid content of the inner membrane of the mitochondria is an important factor for making resistance to peroxides and free radicals of unsaturated fatty acids.

The respiratory chain reaction is a series of electron transfer processes that reduce oxygen to water by enzymatic reactions that occur through the chitochrome enzyme system. Among the various substances produced in this process. However, unsaturated fatty acids are destroyed by abnormal free-radical reactions. The most destructive process in the respiratory chain reaction is the process in which oxygen acquires extra electrons to produce superoxide anion radicals. Most superoxides produced in mitochondria are effectively destroyed by enzymes called superoxide dismutases (SODs), but some react with water to produce hydrogen peroxide (H ₂ O ₂ ). The hydrogen peroxide thus formed was found to exist in high concentrations inside the substrate of the mitochondria even under normal conditions. This hydrogen peroxide is primarily defended by an enzyme called catalase present in the substrate. However, it has been found that this defense system is limited under oxygen stress, and that the optic nerve of the newborn may be destroyed by oxidative stress.

Unsaturated fatty acid peroxides are extremely toxic and damage the biological system. Recent studies have shown that lipid peroxides play a broad role in eye aging, promoting lens opacity, permeability and cataract formation. It has also been reported that lipid peroxides degrade DNA and increase brain nerve lipofuscin, which decreases brain nerve function. This can cause nerve breakdown, reducing nerve cells, Batten's disease, childhood amyloidosis, amyloidosis, Alzheimer's disease, liver fibrosis, hepatitis, cirrhosis, tuberculosis It is also related to changes in liver and kidney caused by painkillers. Lipid peroxides have been shown to reduce cell membrane binding capacity, decrease membrane fluidity and elasticity, and these are carcinogens and have been linked to atherosclerosis, heart disease, gastric ulcers, digestive diseases, gastric cancer, and encephalomalacia. lost.

Carcinogens generally promote the production of reactive oxygen and generate free radicals such as peroxides. Excess free radicals that occur in vivo act as oxidative stress on the living body, leading to aging diseases such as cancer, diabetes, brain diseases, arteriosclerosis, and cataracts. Therefore, antioxidants that inhibit this response are known to inhibit the progression of senile diseases, including cancer.

The defense against lipid peroxides in living organisms is quite sophisticated and efficient. This defense is maintained by a delicate balance between detoxifying enzymes and antioxidants present in cells and antioxidants coming from the body.

There are active studies to delay the development of senile diseases by using antioxidants effectively. Vitamin C, vitamin E, glutathione, catalin, baineiting and catachrome-OFTAN ( Antioxidants such as catachrome-OFTAN, Vita-iodurol and quinax have been used to treat cataracts. However, many of these compounds are suspected to be carcinogenic, causing side effects such as nausea, and side effects such as liver have been reported.

Antioxidants are substances that have the function of preventing the automatic oxidation of fats or fat-containing foods and inhibiting the aging of cells. Antioxidants are classified into free radical inhibitors, metal scavengers, peroxide decomposers, synergists, and superoxide dismutases. Currently, antioxidants are widely used as food additives, including phenolic antioxidants such as BHA (t-butyl hydroxy anisole) and BHT (t-butyl hydroxy toluene). However, ingesting more than 50mg / kg of these substances a day is known to cause cancer due to changes in biological enzymes and fats, and has been reported to damage the liver. Therefore, the discovery of natural antioxidants instead of synthetic antioxidants and not harmful to the human body is a very important task.

Accordingly, it is an object of the present invention to provide an extract of arsi and raspberry having excellent antioxidant effects.

Another object of the present invention is to provide a mixed composition comprising the active ingredient according to the extract of the present invention.

Still another object of the present invention is to provide a method for preparing the extract of the present invention.

Such an object of the present invention can be achieved by extracts extracted with a solvent and wild strawberry.

Since the composition of the present invention is not toxic at first and can be directly orally administered to the human body or added to foods and beverages, the composition is very significant in that it is an antioxidant substance that can be ingested as a supplement.

Hereinafter, the present invention will be described in detail.

Based on the mechanism of the development and progression of the senile disease, the present inventors have an excellent antioxidant function to reduce the oxidative stress, so that the extract of aralia and raspberry may exhibit the effects of preventing and delaying the senile disease, cancer and diabetes. It has been found that the present invention has been reached.

Durul is a plant belonging to the genus Aralia sp., A perennial herb native to East Asia. The shell of the shell contains several types of triterpenoids, including saponins, and the bark contains elatoside E, which has a hypoglycemic effect, such as elatoside F and olenolic acid glycosides. It contains glycosides and elatosides A and B that inhibit ethanol absorption. Oleanolic acid, a type of saponin, prevents acute liver damage caused by various chemicals.

Raspberry is a plant belonging to the genus Rubus, and the less ripe fruit is called Bokbunja. In Korea, bokbunja are mostly berries of wild berries, and sometimes the fruits of bokbunja berries are used. The outpost contains flavonoids and the root contains triterpene saponins. Other organic acids include malic acid and vitamin C. In Dongbogam, bokbunja was used as a tonic medicine, and in folk medicine, leaves were used as sedatives and inflammatory drugs for arthritis and whole liver. Bokbunja is known to activate liver function to enhance vision, make energy and blacken gray hair. In addition, when lack of energy, it is also used for energy loss, oil well, urinary frequency.

In the present invention, the ginseng and raspberries are extracted with water or alcohol. It is particularly preferable that the arbor and raspberry extracts of the present invention are used in a mixture of myo-inositol, taurine, vitamin C, folic acid and pantothenic acid, respectively or simultaneously, for the purpose of reducing oxidative stress. Arali and raspberry extract may be mixed in a ratio of 0.1 to 0.1 to 1.

The present invention provides herbal preparations, health supplements, food additives, and beverages containing the active ingredients of arsi and raspberry extract. The use of arbor and raspberry extract as a herbal or dietary supplement may be administered subcutaneously, orally, intramuscularly or in the form of a therapeutically effective amount alone or in the form of a pharmacologically acceptable carrier, excipient or diluent. It is administered in a variety of ways, including other suitable methods known to. Formulations for oral administration suitable for extracts of the present invention may be in the form of tablets, capsules, solutions, suspensions, syrups, or beverages. Formulations comprising arbor and raspberry extracts for extraoral administration may be in the form of sterile injectables such as sterile, injectable liquids or oily suspensions. The suspension is prepared according to methods well known in the art, using suitable dispersing or wetting agents and suspending agents. The sterile injectables may also be sterile injectable solutions or suspensions containing an orally acceptable diluent or solvent, such as 1,3-butanediol. Suitable diluents include, for example, water, Ringer's solution, and isotonic saline. In addition, sterile, fixed oils can be readily used as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables.

The extract of ars and raspberries of the present invention can be used as a beverage containing water, sweeteners and suitable additives. Myo-inositol or taurine, vitamin C, folic acid, pantothenic acid, citric acid, oligosaccharides and the like may be added to the beverage, and these components may be mixed together. Dried radish and raspberry are foods that have been edible by themselves since ancient times, and the extract extracted therefrom is not toxic, and is provided as a beverage containing appropriate sweeteners and preservatives, so that it can be often used for drinking to prevent senile diseases. In particular, there is an effect of the prevention and treatment of cataracts by the removal of peroxides with respect to the antioxidant effect.

Dose and raspberry extract according to the present invention when using the herbal drug dosage may vary depending on the type of disease, the severity of the disease, the sex, age, weight and desired effect of the patient to be administered. Generally, when administered orally to an adult, a dose of 20-70 mg, preferably 30-50 mg, per kg of body weight per day may be administered, and when administered by injection other than oral, a person weighing 60 kg may be used. Doses of 10-50 mg may be administered as a reference.

According to the present invention, the malt and raspberries are extracted with an aqueous solvent and filtered;

The filtrate was saturated under high pressure to remove the coagulum precipitate produced by centrifugation;

Adding an organic solvent to the filtrate to remove the organic solvent-soluble material, and then separating and drying the aqueous layer;

Provided is a method of preparing a pharmaceutical composition comprising a.

In the method of the present invention, as the solvent, water or alcohol or a mixture of water and alcohol in an appropriate ratio is suitable. Using this aqueous solvent, aralia and raspberries are mixed in a weight ratio of 1: 0.2 to 1: 5, and water is added to the mixture in a weight ratio of 1: 5 to 1:10 and extracted.

Thus, the extract may be extracted by mixing the malt and the raspberry, and the extract extracted by mixing the malt and the aqueous solvent in a weight ratio of 1: 5 to 1:10, and the weight ratio of the raspberry and the aqueous solvent to 1: 5 to 1:10. The same effect can be obtained by mixing the extract extracted by mixing in a weight ratio of 1: 0.2 to 1: 5.

In the process of the present invention, chloroform or hexane can be preferably used as the organic solvent.

Hereinafter, the present invention will be described in detail with reference to Examples, but the scope of the present invention is not limited to these Examples.

Example 1 Extraction of Aralia and Raspberries

Each dried extract was dried and dried by heating with water, and the extracts were mixed at a weight ratio of 1: 1, or the raw materials were mixed and extracted by heating. The extraction method is as follows.

600 g each of the mixture and each of the mixture of the arbor and raspberry were mixed 1: 1 by weight, and 5 L of distilled water was added thereto, followed by extraction, filtration and centrifugation while stirring for 40-50 hours. After centrifugation, 2 L of chloroform was added to the filtrate, and the resin, fiber, protein, and the like were eluted, and then the chloroform layer was removed. To this, n-hexane was added again to elute the remaining resin, fiber, n-hexane soluble substance, and the like. The aqueous layer was recovered, and talc was added to filter and purify to remove talc. The remaining talc was removed by filtration in a membrane filter device and the purified filtrate was lyophilized to powder. By this method, 36g (yield about 6%) of the mixed extract of aralia and raspberries were obtained, 25.8g (yield about 4.3%) and 46.8g (yield about 7.8%) of wild strawberry extract.

Example 2: Preparation of Extract with Alcohol

1,500 ml of 70% methanol was added to 100 g of the powder ground with a grinder, and dried for 50 hours while stirring occasionally. The mixture was filtered under reduced pressure to obtain an alcohol extract, and the residue was removed. Alcohol was recovered from the reflux condenser, and 1,000 ml of distilled water was added to the remaining alcohol extract, mixed, and heated at 100 ° C. for 5 minutes. An appropriate amount of talc was added to this turbid extract, and the mixture was filtered under reduced pressure and purified first. The purified filtrate was added to a fraction funnel, and 300 ml of chloroform was added to elute the resin and the fibres. The chloroform layer was separated and removed, and 200 ml of n-nucleic acid was added to the aqueous layer. And the like was eluted. The aqueous layer was recovered, warmed to 60-80 ° C., and then stirred by adding an appropriate amount of talc again, filtered under reduced pressure to remove talc, and the filtrate was gradually filtered again, and then lyophilized to powder. By this method, about 10 g of the extract was obtained with a yield of about 10% (dry weight basis) in the mixed extract of the aralia and raspberries.

Example 3: Formulations Containing Aralia and Raspberry Extract

1. Tablet

250 mg of the freeze-dried powdered mixed extract of the present invention prepared in Example 1, 260 mg of lactose for excipients and 35 mg of Avicel (microcrystalline cellulose), 15 mg of sodium starch glyconate as a disintegration aid, 80 mg of -HPC (Low-hydroxyprophylcell ulose) was mixed and mixed in a U-type mixer for 20 minutes. After the completion of the mixing, 10 mg of the suspending agent magnesium stearate was further added and mixed for 3 minutes. After quantitative and hygroscopic tests, tableting and film coating were carried out to prepare tablets containing 250 mg of a single extract.

2. Syrup

An appropriate amount of sucrose was dissolved in a certain amount of water, and 80 mg of paraoxymethylbenzoate and 16 mg of paraoxypropylbenzoate were added as a preservative, and the freeze-dried powdered mixed extract of the present invention prepared in Example 1 4.5 g was added, dissolved completely while maintaining at 60 ° C, cooled, and distilled water was added to make 150 ml to prepare a syrup.

3. Capsule

500 mg of the freeze-dried powdered mixed extract of the present invention prepared in Example 1 was filled into a hard gelatin capsule to prepare a capsule.

4. Drink

After dissolving 500 mg of the lyophilized powdered extract of the present invention prepared in Example 1 in an appropriate amount of water, vitamin C as an auxiliary component, citric acid, sodium citrate, oligosaccharides as an auxiliary agent was added, and an appropriate amount of sodium was used as a preservative. After adding benzoate, water was added to make the whole amount 100 ml to prepare a beverage composition. At this time, taurine, myo-inositol, folic acid, pantothenic acid, etc. may be added alone or together.

5. Injection

200 mg of the lyophilized powdered mixed extract of the present invention prepared in Example 1 was dissolved in 200 mg of physiological saline containing 1% polyoxyethylene hydrogenated castro oil, and the mixed extract was contained at a concentration of 0.1%. The formulation was prepared.

Experimental Example 1. Determination of the antioxidant effect of the extract

Antioxidant effect retrieval method using chemiluminescence used in the present experimental example uses the chemiluminescence emitted by the energy emitted in the form of a chemical reaction in the form of light. Since the amount of light generated is very small, cyclic diacylhydrazides such as ABEI (aminobutylethyl isoluminol) are used as an amplifying agent to amplify the light. These substances emit light as they are rapidly oxidized by enzymes in the presence of hydrogen peroxide H ₂ O ₂ as a substrate of peroxidase. When ABEI is oxidized by peroxidase in the presence of H ₂ O ₂ , it emits light and decomposes. In this process, the antioxidant inhibits the oxidation reaction, thereby suppressing the luminescence caused by the oxidation. Therefore, the antioxidant power can be expressed to the extent that suppresses chemiluminescence. Light emission from the oxidation reaction was detected at 428nm.

200 μl of 0.6 μM ABEI and 200 μl of extract (1 mg / ml) were placed in a polystyrene tube and 35% H ₂ O ₂ and 10 mg / ml microperoxidase were diluted 1: 100 and injected automatically into the luminometer. . The intensity of light by chemical reaction was measured for 2 seconds by a luminometer (LB9502, Clilumat, Germany). The antioxidant capacity of the extract was expressed as a percentage of inhibition of the light intensity during the reaction. The results showed that the arbor and raspberry extracts were stronger than the respective extracts as shown in Table 1. This fact shows that there is a synergy between the two, and the antioxidant power is better than vitamin C.

Antioxidant Effect of Extracts of the Present Invention extract Chemiluminescence inhibition% Arbor extract 75% Raspberry Extract 63% Aralia + Raspberry Extract 92% Vitamin c 88%

Experimental Example 2. Effects on the Peroxide Contents of the Mixed Extract of Aralia and Raspberries

MDA (Malonyldialdehyde), a major lipid peroxide that occurs frequently in vivo, is an intermediate of lipid peroxidation process. Polyunsaturated fatty acids having three or more double bonds are caused by oxidative decomposition of free active radicals and are most widely used as indicators of lipid peroxidation. Is used. MDA, a lipid peroxide, is more likely in diabetic situations and is easier to measure because it reacts with thiobarbituric acid (TBA). Therefore, in this experiment, the degree to which the extract of the present invention inhibits the generation of lipid peroxides was investigated by using a diabetes model in which the generation of lipid peroxides was increased.

One group divided 50 rats (SpragueDaweley species, ♂) weighing 150 ~ 170g into two groups and fasted for 16 hours at 6 weeks of age, and then dissolved streptozotocin (Sigma Chemical CO, USA) to 65 mg / kg BW. Diabetes was induced by one injection into the abdominal cavity within 10 minutes. Three days after the induction of diabetes, venous blood of the tail was taken and classified as having induced diabetes only when the fasting blood glucose was 300 mg / dl or more (Kawamura et al, 1987). Diabetes-induced diabetes with a chemical substance was used as a diabetic group after breeding for 8 weeks.

The diabetic group and the normal group were divided into two groups, respectively, to the group 1 and group 1 of the diabetic group. Administered. The other group was intraperitoneally administered the same amount of saline three times a week for eight weeks.

SD-rats were sacrificed with CO ₂ gas and the kidneys and eyes were immediately extracted. In the eye, the lens was extracted and placed in M199 medium (Sigma, USA) containing gentamycin (Gibco, USA, 5 mg / l) and fungizone (Gibco, USA, 0.5 ug / ml) and CO ₂ 5%, air 95%, The cells were cultured in a cell incubator maintained at 37 ° C. The lens and kidney tissues were rapidly frozen with liquid nitrogen and stored at -80 ° C. Then, within one week, 100 mM potassium phosphate buffer (pH 7.0) was added, homogenized at 4 ° C, and centrifuged at 10,000 x g for 20 minutes. Was stored at -80 ° C and used.

The content of thiobarbituric acid reacting substances representing lipid peroxide content was measured by the method of Ohkawa ( Anal. Biochem. 95: 351-356). At this time, tetraethoxypropane was dissolved in methanol as a standard solution.

As a result, as shown in Table 2, the administration of the mixed extract of the present invention was found to have a significant effect on the production of TBARS in kidney and lens homogenate. That is, in the diabetic group, the saline-administered group (diabetic control group) showed a TBARS content of about 2.4 times that of the normal group. When the mixed extract of the present invention was administered to the diabetic group, the TBARS content was reduced by 66% to about 34% of the diabetic control group, and in the normal group, the administration of the mixed extract of the present invention did not show a significant difference. .

In the homogeneous solution of the lens, the TBARS content of the diabetic control group was increased by 7 times or more than that of the normal control group, and decreased to 23% of the diabetic control group when the diabetic group was administered the mixed extract of the present invention. The significant increase in kidney and lens TBARS in the diabetic group reflects the oxidative stress of tissues. The decrease in the content of TBARS when the mixed extract of the present invention is administered means that the mixed extract of the present invention can delay the progression of the disease by protecting the tissue from oxidative stress.

Effect of Extract of the Invention on Lipid Peroxide Production Fauna drug injection kidney Lens Normal Physiological saline administration (n = 10) 0.36 ± 0.04 0.23 ± 0.02 Mixed extract administration of the present invention (n = 10) 0.29 ± 0.02 0.20 ± 0.01 Diabetes Physiological saline administration (n = 9) 0.88 ± 0.03 1.59 ± 0.04 Mixed extract administration of the present invention (n = 8) 0.30 ± 0.01 0.37 ± 0.02

Example 4 Toxicity Experiments on Aralia and Raspberry Extracts According to the Present Invention

LD ₅₀ (50% of experimental animals that can kill 50% of experimental animals) is an important value that is an indicator of acute toxicity of drugs in order to confirm the safety when using arbor and raspberry extract according to the present invention as a herbal or dietary supplement. Yang) value was obtained by the following method.

Sixty normal ICR mice (male, 22 ± 1 g) were divided into six groups of A to F, each six in a group, and the group A and raspberries prepared in Example 3 according to the present invention per kg of body weight in group A. Equivalently from administering 5 g of extract, 7.5 g in group B, 10 g in group C, 12.5 g in group D and 15 g in group E, respectively, and the Berens-Kaber method ( Reference: 高木 敬 次 郞 外: 藥物 實驗, 南山 堂, Japan, p131, 1960) LD50 values were determined by oral (po) administration of the extract of the present invention. The results are shown in Table 3 below.

Lethal dose (LD50) by oral administration of arbor and raspberry extract Experimental group Capacity (g / kg) Oral administration group (p.o.) * Z ** d Number of dead animals A 5 0/6 - - B 7.5 0/6 0 2.5 C 10 0/6 0 2.5 D 12.5 0/6 0 2.5 E 15 0/6 0 2.5

* Z: ½ of the number of dead animals in two consecutive doses

** d: difference between two consecutive doses

As shown in the results shown in Table 3, the LD50 value of oral administration of the ulm and raspberry extract according to the present invention was 15 g / kg or more, and thus it was found to be a very safe substance. That is, it can be clearly seen that the ul and raspberry extract according to the present invention can be safely administered with little toxicity.

In addition, autopsies and histopathological examinations were performed on the test animals used to measure the LD50 value in the following manner. At the end of the test, all surviving animals were bled after ether anesthesia, and the organs were extracted and visually examined for all organ abnormalities. Autopsied whole organs were fixed in 10% neutral formalin solution for more than 10 days for pathological examination, and then dehydrated and embedded in a paraffin embedding machine (Fisher, Histomatic Tissue Processor, 166A), followed by an AO Rotary Microtome. 5 μm sections were prepared and observed by hematoxylin and eosin staining.

All animals in each group were dissected, and histologic findings examined under a microscope after HE staining were as follows. When the extract of the present invention was administered up to 15 g / kg of mouse body weight, ideal findings by drug administration were not observed in liver tissue and kidney. In addition, no abnormal findings were observed in the cardiomyocytes of the heart, stomach and intestine, pancreas, lung, spleen, adrenal gland, brain, testes, ovaries, bone marrow, etc. by administration of the extracts of arrhythmia and raspberries.

Therefore, even if the ginseng and raspberry extract according to the present invention was administered 15 g per 1 kg of body weight, the maximum dose that can be administered to the mouse, there was no side effect due to acute toxicity to all organs, and also no toxicity such as any organ damage. It was determined to be a safe substance that did not cause it.

Although the present invention has been described in detail with reference to the above preferred embodiments, the scope of the present invention is not limited thereto, and substitutions, modifications, and changes apparent to those skilled in the art within the spirit and scope of the present invention are within the scope of the present invention. It should be understood to belong to.

As can be seen from the above description, the extracts of ars and raspberries according to the present invention have strong antioxidant activity and inhibit the production of lipid peroxides in the diabetic model, thereby exhibiting an effect of delaying the progression of diseases such as diabetes. Arsenal and raspberry extract of the present invention is not toxic and has fewer side effects, and can be taken and administered for a long time. In addition, the present invention does not lead to dependencies and resistance.

The extract of the present invention is particularly effective in the prevention of senile diseases, delay in progress, treatment and recovery by protecting tissues from oxidative stress.

Claims (18)

Oxidation inhibiting composition of unsaturated fatty acids in vivo comprising a solvent extract of the aralia and wild strawberry in a weight ratio of 1: 0.2 to 1: 5. The composition of claim 1 wherein said solvent is selected from the group consisting of water and alcohols. delete delete The composition of claim 1, which is administered in an amount of 10 to 50 mg per kg body weight of the adult. The composition of claim 1 wherein the composition is formulated by adding a pharmaceutically acceptable excipient in the form of a tablet, capsule, solution, suspension, syrup or edible beverage. delete The composition of claim 1, wherein the composition is selected from the group consisting of herbal preparations, dietary supplements and beverages. The composition according to claim 1, which is effective in preventing or delaying the progression of senile diseases such as diabetes, brain diseases, arteriosclerosis or cataracts. The method according to any one of claims 1, 2, 5, 6, 8 and 9, wherein the group is composed of myo-inositol or taurine, vitamin C, folic acid, pantothenic acid, citric acid. A composition further comprising one or more compounds selected. Mixing the malt and raspberries in a weight ratio of 1: 0.2 to 1: 5, extracting and filtering by adding an aqueous solvent to the mixture in a weight ratio of 1: 5 to 1:10, Centrifuging and removing the precipitate of coagulated protein produced by saturating the filtrate under high pressure, and A method of preparing a pharmaceutical composition comprising adding an organic solvent to the filtrate to remove the organic solvent-soluble material and then separating and drying the aqueous layer. The method of claim 11, wherein said aqueous solvent is water or an alcohol. delete The extract of claim 11, wherein the extract is obtained by mixing the arbor and the aqueous solvent in a weight ratio of 1: 5 to 1:10, and the extract extracted by mixing the raspberry and the aqueous solvent in a weight ratio of 1: 5 to 1:10. Mixing in a weight ratio of: 0.2 to 1: 5. The method of claim 11, wherein chloroform or hexane is used as the organic solvent. A prophylactic and therapeutic agent for senile diseases, such as diabetes, brain disease, arteriosclerosis, or cataracts, formulated in a pharmaceutical unit dosage form by adding a pharmaceutically acceptable carrier, excipient, or diluent to the mixed extract of arsi and raspberries. A cataract prevention and treatment agent formulated in a pharmaceutical unit dosage form by adding a pharmaceutically acceptable carrier, excipient or diluent to the mixed extract of arsi and raspberries. 18. The prophylactic and therapeutic agent according to claim 16 or 17, wherein the pharmaceutical unit dosage form is a tablet, a capsule, a solution, a suspension, a syrup, a drink, or an injection.